Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 14;77(2):558–572. doi: 10.1002/hep.32620

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of American Association for the Study of Liver Diseases.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Plasma triggering receptor expressed on myeloid cells 2 (TREM2) levels are strongly associated with NAFLD progression. Distribution of subjects according to NASH Clinical Research Network histologic scoring system for (A) steatosis, (B) hepatocellular ballooning, and (C) lobular inflammation. Correlation between plasma TREM2 levels and plasma aspartate aminotransferase (AST) levels (D), and FibroScan‐AST score (E) in patients with biopsy‐proven NAFLD. (F) Logistic regression analysis for the prediction of NASH in the validation cohort (n = 170) patients with biopsy‐proven NAFLD. ALT, alanine aminotransferase; BMI, body mass index; HbA1c, hemoglobin A1c; OR, odds ratio.